vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -76.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -4.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
ESPR vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $334.0M |
| Net Profit | — | $-60.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | -18.0% |
| Revenue YoY | 143.7% | -76.3% |
| Net Profit YoY | — | -170.6% |
| EPS (diluted) | $0.32 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $168.4M | $334.0M | ||
| Q3 25 | $87.3M | $382.0M | ||
| Q2 25 | $82.4M | $397.0M | ||
| Q1 25 | $65.0M | $316.0M | ||
| Q4 24 | $69.1M | $336.0M | ||
| Q3 24 | $51.6M | $396.0M | ||
| Q2 24 | $73.8M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | — | $-60.0M | ||
| Q3 25 | $-31.3M | $105.0M | ||
| Q2 25 | $-12.7M | $87.0M | ||
| Q1 25 | $-40.5M | $61.0M | ||
| Q4 24 | — | $85.0M | ||
| Q3 24 | $-29.5M | $102.0M | ||
| Q2 24 | $-61.9M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | -11.4% | ||
| Q3 25 | -11.4% | 46.6% | ||
| Q2 25 | 8.6% | 37.8% | ||
| Q1 25 | -34.0% | 35.4% | ||
| Q4 24 | -6.4% | 38.4% | ||
| Q3 24 | -31.0% | 43.2% | ||
| Q2 24 | 3.5% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | — | -18.0% | ||
| Q3 25 | -35.9% | 27.5% | ||
| Q2 25 | -15.4% | 21.9% | ||
| Q1 25 | -62.2% | 19.3% | ||
| Q4 24 | — | 25.3% | ||
| Q3 24 | -57.2% | 25.8% | ||
| Q2 24 | -83.9% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.32 | $-0.77 | ||
| Q3 25 | $-0.16 | $1.36 | ||
| Q2 25 | $-0.06 | $1.13 | ||
| Q1 25 | $-0.21 | $0.78 | ||
| Q4 24 | $-0.14 | $1.06 | ||
| Q3 24 | $-0.15 | $1.29 | ||
| Q2 24 | $-0.33 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $64.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $468.0M |
| Total Assets | $465.9M | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $167.9M | $64.0M | ||
| Q3 25 | $92.4M | $70.0M | ||
| Q2 25 | $86.1M | $50.0M | ||
| Q1 25 | $114.6M | $48.0M | ||
| Q4 24 | $144.8M | $103.0M | ||
| Q3 24 | $144.7M | $72.0M | ||
| Q2 24 | $189.3M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $-302.0M | $468.0M | ||
| Q3 25 | $-451.4M | $583.0M | ||
| Q2 25 | $-433.5M | $570.0M | ||
| Q1 25 | $-426.2M | $579.0M | ||
| Q4 24 | $-388.7M | $650.0M | ||
| Q3 24 | $-370.2M | $583.0M | ||
| Q2 24 | $-344.2M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $465.9M | $4.2B | ||
| Q3 25 | $364.0M | $4.3B | ||
| Q2 25 | $347.1M | $4.3B | ||
| Q1 25 | $324.0M | $4.2B | ||
| Q4 24 | $343.8M | $4.2B | ||
| Q3 24 | $314.1M | $4.2B | ||
| Q2 24 | $352.3M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | — | 4.44× | ||
| Q1 25 | — | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $367.0M |
| Free Cash FlowOCF − Capex | — | $168.0M |
| FCF MarginFCF / Revenue | — | 50.3% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $45.2M | $152.0M | ||
| Q3 25 | $-4.3M | $86.0M | ||
| Q2 25 | $-31.4M | $70.0M | ||
| Q1 25 | $-22.6M | $59.0M | ||
| Q4 24 | $-35.0M | $134.0M | ||
| Q3 24 | $-35.3M | $79.0M | ||
| Q2 24 | $-7.2M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | — | $75.0M | ||
| Q2 25 | — | $58.0M | ||
| Q1 25 | — | $52.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | $-35.5M | $71.0M | ||
| Q2 24 | $-7.3M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | — | 40.7% | ||
| Q3 25 | — | 19.6% | ||
| Q2 25 | — | 14.6% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | -68.7% | 17.9% | ||
| Q2 24 | -9.9% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.8% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 7.4% | ||
| Q3 24 | 0.3% | 2.0% | ||
| Q2 24 | 0.1% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
